In a special edition of Oncology On the Go, Chinmay Jani, MD, joined CancerNetwork® in the studio to speak about different research initiatives he is involved with across precision oncology. He discussed ongoing work dedicated to validating and applying artificial intelligence (AI)–based tools in clinical work as well as overcoming immunotherapy resistance among patients with lung cancer. Jani, chief fellow in Hematology and Oncology at University of Miami Sylvester Comprehensive Cancer Center, ...
Jun 22, 2026•23 min•Season 1Ep. 220
Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment, clinical teams frequently encounter behaviors that get unfairly lumped into the vague and pejorati...
Jun 15, 2026•36 min•Season 1Ep. 219
In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations. Braunstein is...
Jun 08, 2026•24 min•Season 1Ep. 218
In a conversation with CancerNetwork®, Nathan Goodyear, MD , spoke about the role that exercise and lifestyle intervention can play in the treatment of patients with cancer. He described how prescribed exercise may serve as a biologically interventional therapy that can help prolong longevity, reduce the risk of recurrence; and supplement the efficacy of standard therapeutic approaches like chemotherapy, immunotherapy, and surgery. Goodyear, an integrative medicine physician at the Williams Canc...
Jun 01, 2026•29 min•Season 1Ep. 217
In a recent interview with CancerNetwork®, Nicholas Hornstein, MD, PhD, an assistant professor at the Donald and Barbara Zucker School of Medicine of Hofstra University and Northwell Health, discussed emerging data and clinical shifts in the care of patients with gastrointestinal (GI) cancers ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting . Advancements in Colorectal Cancer Hornstein highlighted the increasing integration of targeted therapies into the first-line s...
May 28, 2026•29 min•Season 1Ep. 216
In a cobranded episode between Oncology on the Go , hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of gra...
May 25, 2026•11 min•Season 1Ep. 215
Results from the first-in-human, phase 1 MYTHIC trial (NCT04855656) demonstrated that combining the WEE1 inhibitor zedoresertib with the PYKMT1 inhibitor lunresertib achieved an overall response rate (ORR) of 18.5% via RECIST criteria in patients with CCNE1 , FBXW7 , and PPP2R1A -altered cancers.1 In patients with resistant/refractory ovarian cancer, the ORR was 33.3% across all dose levels and 50% at the potential recommended phase 2 dose. These data were presented by Timothy A. Yap, MBBS, PhD,...
May 18, 2026•13 min•Season 1Ep. 214
Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, and Barry Paul, MD, spoke with CancerNetwork® about high-level takeaways that emerged during the meeting. They discussed how CAR T-cell therapies, bispecific antibodies, and other novel modalities currently fit into the treatment paradigm across multiple myeloma, leukemia, lymphoma, and other hematologic oncology populations. The experts first discussed ideas from a session d...
May 11, 2026•12 min•Season 1Ep. 213
In a conversation with CancerNetwork®, Diane Simeone, MD, discussed the implications of daraxonrasib demonstrating meaningful improvements in survival among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the phase 3 RASolute 302 trial (NCT06625320). Topline findings from the trial showed that the novel multiselective RAS(ON) inhibitor approximately doubled the median overall survival (OS) compared with investigator’s choice of chemotherapy, with survival benefits extending t...
May 04, 2026•20 min•Season 1Ep. 212
In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks , host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–related lymphomas developing in the gastrointestinal tract. The study focused on a particular case inv...
Apr 27, 2026•20 min•Season 1Ep. 211
At the 3rd Biennial Miami Precision Medicine Conference, CancerNetwork® spoke with a variety of researchers and clinicians who presented on different topics regarding the use of targeted therapies across several cancer types. Faculty from the University of Miami Sylvester Comprehensive Cancer Center shared key advances and ongoing initiatives across pancreatic cancer, sarcomas, genitourinary malignancies, and other diseases. First, Jashodeep Datta, MD, an associate professor of surgery, a co-lea...
Apr 20, 2026•15 min•Season 1Ep. 210
In a conversation with CancerNetwork®, Shari Goldfarb, MD spoke about key developments and challenges regarding the treatment of younger populations with breast cancer. Key areas across the field included the rising incidence of disease, including HER2-positive and triple-negative subtypes; expanding opportunities for clinical trial enrollment; and preserving fertility among patients undergoing treatment, among other focuses. Although it’s not entirely clear why breast cancer diagnoses are becom...
Apr 13, 2026•19 min•Season 1Ep. 209
In this episode recorded at the 2026 American Psychosocial Oncology Society (APOS) annual meeting, Daniel C. McFarland, DO, sat down with Kelly Irwin, MD, to address one of the most challenging topics in oncology: suicide risk. The conversation aimed to equip oncologists with the tools and confidence to navigate the emotional complexities of cancer care. Key Discussion Points: Understanding the Risk: Patients with cancer experience more than double the risk of completed suicide compared with the...
Apr 06, 2026•39 min•Season 1Ep. 208
In a conversation with CancerNetwork®, Julian Hong, MD, MS, discussed considerations for optimizing care among patients with mental health disorders (MHDs) who are undergoing treatment for cancer. He spoke in the context of a study he and coauthors published in Cancer, which showed that patients with cancer and a mental health condition experience an increased risk of all-cause mortality. Specifically, findings from the study demonstrated that early MHDs conferred a heightened all-cause mortalit...
Mar 30, 2026•21 min•Season 1Ep. 207
In this episode of Oncology on The Go , created in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, and Ilana M. Braun, MD, dove into the complexities of cannabis use within the oncology landscape. They explored the tension between rising public popularity and the need for rigorous scientific scrutiny in symptom management. Key Discussion Points: The 2024 ASCO Guidelines: Braun highlighted the first-of-its-kind clinical guidelines from the American Society ...
Mar 23, 2026•31 min•Season 1Ep. 206
During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations. First, Nicole Lamanna, MD, an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hemato...
Mar 16, 2026•23 min•Season 1Ep. 205
In a conversation with CancerNetwork®, Sagar Lonial, MD, FACP, FASCO, discussed the potential implications of the FDA approving iberdomide plus daratumumab (Darzalex) and dexamethasone for patients with relapsed/refractory multiple myeloma. He spoke in context of the FDA accepting a new drug application for the iberdomide regimen based on data from the phase 3 EXCALIBER-RRMM trial (NCT04975997). Lonial discussed the potential benefits that iberdomide could offer based on its properties as a CELM...
Mar 09, 2026•10 min•Season 1Ep. 204
Daniel C. McFarland, DO, and Boris Kiselev, MD, highlighted the need for oncologists to recognize and address depression for patients with cancer. In a new episode of Oncology on the Go created in collaboration with the American Psychosocial Oncology Society, host Daniel C. McFarland, DO, spoke with Boris Kiselev, MD. Together, they explored the complex intersection of oncology and psychiatry. The conversation challenged the oversimplification of “cancer-related sadness” to provide clinicians wi...
Mar 02, 2026•49 min•Season 1Ep. 203
Sarah Poland, MD, lead author of a recently published article in the journal ONCOLOGY titled Advances in Immunotherapy for Breast Cancer , highlighted key findings from her review in a conversation with CancerNetwork®.1 Throughout the discussion, she spoke about: Shifting Perspectives on Immunogenicity : Historically, breast cancer was considered a “cold,” poorly immunogenic tumor due to low tumor mutational burden (TMB) and few tumor-infiltrating lymphocytes (TILs). Poland highlighted how clini...
Feb 23, 2026•27 min•Season 1Ep. 202
At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types. First, Fernando Duarte, head of the Bone Marrow Transplant Service at Walter Cantídio University Hospital (HUWC)...
Feb 16, 2026•11 min•Season 1Ep. 201
In a conversation with CancerNetwork®, Manoj Bhasin, PhD, MS, spoke about findings from a study in which he and colleagues developed a single-cell atlas characterizing the dysregulation of the bone marrow immune microenvironment in newly diagnosed multiple myeloma. Findings published in Nature Cancer showed that the immune system has a broad, treatment-independent influence on outcomes in newly diagnosed multiple myeloma. Bhasin began by detailing the background and methodology of his study, in ...
Feb 09, 2026•16 min•Season 1Ep. 200
In a conversation with CancerNetwork®, Ram Prakash Thirugnanasambandam, MBBS, discussed the evolving roles that artificial intelligence (AI)–based tools may play in palliative care and the management of different hematologic malignancies. He spoke in the context of a publication he authored, The Role of Artificial Intelligence in Palliative Oncology: Zeroing in on Hematologic Malignancies, which was featured in the November/December 2025 issue of the journal ONCOLOGY® . Thirugnanasambandam, a fe...
Feb 02, 2026•11 min•Season 1Ep. 199
Emphasizing the evidence-based nature of medicine, Nathan Goodyear, MD, explained that integrative oncology uses many of the same parameters and key clinical thresholds among patients undergoing treatment for a diagnosis of cancer that his conventional oncologist colleagues use. In this episode of Oncology on the Go , Goodyear, an integrative medicine physician at the Williams Cancer Institute, discussed key clinical efficacy and safety thresholds that integrative oncologists use for flagship in...
Jan 26, 2026•23 min•Season 1Ep. 198
In a conversation with CancerNetwork®, Kandace P. McGuire, MD, and Paschalia Mountziaris, MD, PhD, highlighted the use of L-Dex bioimpedance spectroscopy as a method for detecting lymphedema earlier in patients who undergo surgery for breast cancer. The experts discussed seamlessly integrating this novel modality into standard vitals workflows and detailed other considerations for improving long-term survivorship outcomes via proactive lymphatic care. McGuire began by breaking down why detection...
Jan 19, 2026•21 min•Season 1Ep. 197
In a conversation with CancerNetwork®, Nathan Goodyear, MD, provided an overview of how to implement integrative modalities that may effectively supplement standard-of-care oncologic therapies. Beyond the use of intravenous vitamin C and other flagship strategies at his institution, Goodyear addressed potential misconceptions and biases surrounding integrative oncology and discussed how to re-engage patients back into evidence-based care. Goodyear, an integrative oncologist at the Williams Cance...
Jan 12, 2026•28 min•Season 1Ep. 196
In a conversation with CancerNetwork®, Jose G. Trevino, II, MD, FACS, spoke about the current state of the pancreatic ductal adenocarcinoma (PDAC) paradigm as well as next steps for improving the prognosis of patients who present with this disease. Throughout the discussion, Trevino outlined the roles that surgical oncologists can play in disease management, the different demographic and socioeconomic drivers of disparate patient outcomes, and translational research focusing on factors like the ...
Jan 05, 2026•16 min•Season 1Ep. 195
After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes. Adams and Banerjee discu...
Dec 29, 2025•28 min•Season 1Ep. 194
This episode of the collaborative podcast between Oncology on the Go and the American Psychosocial Oncology Society (APOS), hosted by Daniel C. McFarland, DO, features Michelle B. Riba, MD, and focuses on integrating psychosocial care into oncology for clinicians. The discussion emphasizes that psychosocial issues profoundly impact both quality of life and cancer-related outcomes, making their assessment an integral part of care, not merely ancillary. The distress thermometer was developed by th...
Dec 22, 2025•48 min•Season 1Ep. 193
At the 2025 American Society of Hematology Annual Meeting & Exposition (ASH), CancerNetwork® sat down with a variety of researchers and clinicians to discuss potential advancements across hematologic oncology care. These experts shared their findings related to investigational therapeutic regimens and strategies that may prove impactful across different multiple myeloma, lymphoma, and leukemia populations. First, Krina K. Patel, MD, MSc, highlighted findings from the phase 2 iMMagine-1 study...
Dec 15, 2025•10 min•Season 1Ep. 192
In the most recent ONCOLOGY On the Go hosted in collaboration with the American Psychosocial Oncology Society, Daniel C. McFarland, DO, spoke with Charles S. Kamen, PhD, MPH, about health equity for sexual and gender minority groups in oncology. Sexual and gender minority groups, who constitute approximately 9.3% of the US population, experience significant and preventable disparities across all stages of the cancer care continuum, according to Kamen.1 He detailed how these inequities are largel...
Dec 08, 2025•54 min•Season 1Ep. 191
